Patients with hepatitis C virus-related decompensated
cirrhosis can benefit from
interferon-based
antiviral therapy, but the common complication of
cytopenia is a
contraindication for this treatment.
Splenectomy prior to
interferon therapy may alleviate this problem. To investigate whether
splenectomy improves the efficacy of
antiviral therapy, 13
interferon-naïve hepatitis C virus decompensated cirrhotic patients underwent
splenectomy between January 2008 and January 2011, followed 1-3 months later by an
interferon-based therapeutic regimen (pegylated/standard
interferon-α combined with
ribavirin for 48 weeks). Ten (76.9%) of the patients developed postoperative complications, which included minor portal vein
thrombosis (2/13, 15.4%) and transient
ascites (8/13, 61.5%). At one-month post-
splenectomy, the patients showed significantly increased platelet (pre-surgery: 48.2±15.9 vs. 186.0±70.6×10(3)μL(-1), p<0.001) and leukocyte (2.1±0.5 vs. 5.7±1.4×10(3)μL(-1), p<0.001) counts. Eight (61.5%) of the patients achieved sustained virological response, including all HCV genotype 2a-infected patients (4/4, 100%) and some of the genotype 1b-infected patients (4/9, 44.4%). Temporary
interferon-α
suspension was required for one patient to address severe intestinal
infection. These results indicate that
splenectomy prior to
interferon-based
therapy was safe and may facilitate adherence to subsequent
antiviral therapy in selected HCV cirrhotic patients with
portal hypertension and
hypersplenism.